Egetis Therapeutics AB (OSTO:EGTX) Cyclically Adjusted PS Ratio: (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:EGTX Egetis Therapeutics AB OSTO:EGTX
65 GF Score
Price kr6.80
GF Value kr5.65
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Egetis Therapeutics AB  (OSTO:EGTX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Egetis Therapeutics AB Cyclically Adjusted PS Ratio Related Terms


Egetis Therapeutics AB Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Egetis Therapeutics AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB Cyclically Adjusted PS Ratio Chart

Egetis Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.21 9.96 8.42 11.69 9.71

Egetis Therapeutics AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.97 9.90 9.71 10.21 0.00

OSTO:EGTX vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Egetis Therapeutics AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Cyclically Adjusted PS Ratio falls into.


OSTO:EGTX
65GF Score
Egetis Therapeutics AB OSTO:EGTX
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egetis Therapeutics AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Egetis Therapeutics AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Egetis Therapeutics AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.038/134.6100*134.6100
=0.038

Current CPI (Jun. 2026) = 134.6100.

Egetis Therapeutics AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.000 101.138 0.000
201612 0.000 102.022 0.000
201703 0.000 102.022 0.000
201706 0.003 102.752 0.004
201709 0.000 103.279 0.000
201712 0.252 103.793 0.327
201803 0.014 103.962 0.018
201806 0.180 104.875 0.231
201809 0.125 105.679 0.159
201812 0.206 105.912 0.262
201903 1.020 105.886 1.297
201906 0.079 106.742 0.100
201909 0.104 107.214 0.131
201912 0.359 107.766 0.448
202003 0.201 106.563 0.254
202006 0.368 107.498 0.461
202009 0.044 107.635 0.055
202012 0.027 108.296 0.034
202103 0.021 108.360 0.026
202106 0.139 108.928 0.172
202109 0.034 110.338 0.041
202112 0.018 112.486 0.022
202203 0.039 114.825 0.046
202206 0.024 118.384 0.027
202209 0.024 122.296 0.026
202212 0.034 126.365 0.036
202303 0.028 127.042 0.030
202306 0.023 129.407 0.024
202309 0.049 130.224 0.051
202312 0.112 131.912 0.114
202403 0.041 132.205 0.042
202406 0.046 132.716 0.047
202409 0.032 132.304 0.033
202412 0.031 132.987 0.031
202503 0.035 132.825 0.035
202506 0.040 133.699 0.040
202509 0.048 133.480 0.048
202512 0.045 133.390 0.045
202603 0.033 133.560 0.033
202606 0.038 134.610 0.038

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Egetis Therapeutics AB (OSTO:EGTX) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of kr6.80 is trading 20.4% above its estimated GF Value™ of kr5.65. GuruFocus considers Egetis Therapeutics AB to be Modestly Overvalued.

Key valuation signals for OSTO:EGTX:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: kr5.65 vs. price of kr6.80 (20.4% above fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the OSTO:EGTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Egetis Therapeutics AB Business Description

Other Exchanges PDPHF:USA0ABW:UKP0F:Germany
Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
65GF Score

Get the complete analysis for OSTO:EGTX

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.80
Price
kr5.65
GF Value